E-mail: voglova@fnhk.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- ABNORMALITY OF GLUCOSE AND LIPID METABOLISM DURING NILOTINIB THERAPY – RESULTS OF ENIGMA 2 STUDY
- ANALYSIS OF 1458 ACUTE MYELOID LEUKEMIA FROM THE ALERT PROJECT (ACUTE LEUKEMIA CLINICAL REGISTER) IN THE CZECH REPUBLIC IN 1996-2006
- ANGIOGENIC ACTIVATORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: EFFECT OF TREATMENT WITH IMATINIB MESYLATE
- ARE FLT3 ITD AND D835 MUTATIONS SUFFICIENT INDICATORS FOR ALLOGENEIC TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA? AN ANALYSIS OF PATIENTS FROM THE CZECH ACUTE LEUKEMIA CLINICAL REGISTER (ALERT)
- ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS OF TRANSPORT PROTEINS SLC22A1, ABCB1 AND ABCG2 WITH RESPONSE TO IMATINIB AND IMATINIB PLASMA LEVEL IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
- Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
- COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND IMATINIB FOR CHRONIC MYELOID LEUKEMIA: RESULTS FROM CAMELIA REGISTRY
- Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study
- Early PK-Analysis Predicts Molecular Response In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib
- CHRONIC EOSINOPHILIC LEUKEMIA ASSOCIATED WITH T(5;16)(Q32;P13) SENSITIVE TO IMATINIB
- IMATINIB MESYLATE SIGNIFICANTLY DECREASES PLASMA LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND SOLUBLE ENDOGLIN BUT NOT BASIC FIBROBLAST GROWTH FACTOR IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
- Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile
- IS DETECTION OF CYP3A5*3 ALLELE IN CHRONIC MYELOID LEUKEMIA PATIENTS PRIOR TO TREATMENT WITH IMATINIB MESYLATE RELEVANT?
- Model klinického registru umožňujícího hodnocení léčebné péče: projekt ALERT (Akutní LEukémie – klinický RegisTr)
- ORAL FLUDARABINE AND CYCLOPHOSPHAMIDE PLUS RITUXIMAB (FCR) IS A SAFE AND EFFECTIVE SALVAGE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA AND FOLLICULAR LYMPHOMA.
- Plasma concentrations of angiogenic activators VEGF and bFGF in patients with multiple myeloma, follicular lymphoma, diffuse large B-cell lymphoma, and chronic myeloid leukemia
- Plasma levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble endoglin (sCD105) in patients with chronic myeloid leukemia: impact of treatment with imatinib mesylate.
- PROGNOSTIC INFLUENCE OF ELEVATED PRETRANSPLANT SERUM FERRITIN ON THE RESULTS AFTER ALLOGENIC HEMATOPOETIC STEM CELL TRANSPLANTATION
- Přídatné chromosomové změny u pacientů s CML léčených preparátem Glivec
- RESPONSE OF SECONDARY CHRONIC MYELOID LEUKEMIA TO IMATINIB. COOPERATIVE STUDY OF CML REGISTRIES CAMELIA AND INFINITY
- RETROSPECTIVE ANALYSIS OF TREATMENT OF PRIMARY PROGRESSIVE AND/OR RELAPSED HODGKIN’S DISEASE IN 1996 - 2004
- Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study
- Successful Treatment with Imatinib Mesylate Significantly Decreases Plasma Levels of Vascular Endothelial Growth Factor (VEGF) and Soluble Endoglin (sCD105) but Not Basic Fibroblast Growth Factor (bFGF) or Angiopoietin-2 (Ang-2) in Patients with Chro
- The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–20
- TREATMENT WITH NILOTINIB IN EARLY CHRONIC PHASE CML–FIRST RESULTS FROM THE ENEST1ST SUB STUDY CAMN107EIC01
